{
    "id": 32338,
    "fullName": "EGFR W817*",
    "impact": "nonsense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR W817* results in a premature truncation in the protein kinase domain of the Egfr protein at amino acid 817 of 1210 (UniProt.org). W817* has been identified in the scientific literature (PMID: 31715539), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jan 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17697,
                    "pubMedId": 31715539,
                    "title": "Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31715539"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "W817*",
    "createDate": "01/29/2020",
    "updateDate": "01/29/2020",
    "referenceTranscriptCoordinates": {
        "id": 187162,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181459G>A",
        "cDna": "c.2450G>A",
        "protein": "p.W817*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20100,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tarceva (erlotinib) treatment in combination with chemotherapy resulted in progressive disease with a progression-free survival of 4 months in a patient with non-small cell lung cancer harboring EGFR W817* (PMID: 31715539).",
            "molecularProfile": {
                "id": 34855,
                "profileName": "EGFR W817*"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17697,
                    "pubMedId": 31715539,
                    "title": "Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31715539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34855,
            "profileName": "EGFR W817*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 187162,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181459G>A",
            "cDna": "c.2450G>A",
            "protein": "p.W817*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}